Immunotherapy Use Does Not Correlate With Increased Mortality in Patients with COVID-19, Cancer
Treatment with immune checkpoint inhibitors did not increase the risk of mortality in patients with COVID-19 and cancer.
Related Articles
Global Cancer Statistics Report Provides Insights into Cancer Incidence and Mortality
The Global Cancer Statistics, 2024, report from the American Cancer Society sheds light on worldwide cancer facts, identifying trends and making predictions for the future.
Investigational Vaccine TG4050 Shows Early Clinical Benefit in HPV– Head and Neck Cancers
Phase 1 data of TG4050 elicited tumor-specific immune responses that resulted in low relapse rates in patients with resected HPV–negative head and neck cancers.
Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer
Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.
Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
Saruparib’s favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC
Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.
Dr Sekeres on Using MDS Risk-Stratification Systems in Clinical Practice
Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.
Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer
Mirvetuximab soravtansine plus pembrolizumab in patients with recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer, according to findings from a phase 2 trial.
FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer
The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.